内容紹介
A Three-Week Regimen of S-1 Monotherapy Reduced Gastrointestinal Toxicity and Maintained Efficacy in Patients with Gemcitabine-Refractory Advanced Pancreatic Cancer
Summary
S-1 administration for 28 consecutive days followed by 14 days of rest(6-week cycle)is often chosen as second-line chemotherapy for advanced pancreatic cancer(PC), but it causes gastrointestinal toxicity. In comparison, in gastric cancer or head and neck cancer, S-1 administration for 14 consecutive days followed by a 7-day rest period(3-week cycle)reduced gastrointestinal toxicity. This study retrospectively evaluated the efficacy and safety of a 3-week S-1 schedule compared to a 6-week schedule in patients with gemcitabine(GEM)-refractory advanced PC. Fifty-seven patients were treated with the 6-week S-1 schedule and 68 patients were treated with the 3-week S-1 schedule. There were no statistical differences in overall survival(p=0.13)and progression-free survival(p=0.190). With regard to adverse events, the rates of nausea(p<0.01)and vomiting(p=0.04)were lower with the 3-week schedule than with the 6-week schedule. Thus, S-1 therapy with a 3-week schedule as second-line chemotherapy in patients with GEM-refractory advanced PC was associated with reduced gastrointestinal toxicity and similar efficacy, when compared to a 6-week schedule.
要旨
S-1の推奨用法は4週投与2週休薬(6週サイクル)であるが,胃癌や頭頸部癌において投与スケジュールを2週投与1週休薬(3週サイクル)に短縮することで,消化器毒性が軽減することが報告されている。本研究では,ゲムシタビン耐性進行膵癌に対してS-1療法を受けた患者125名(6週サイクル57名,3週サイクル68名)を対象として,投与スケジュール別の治療成績を比較検討した。両群間の全生存期間に差を認めないが,悪心や嘔吐の発現割合が3週サイクルで低下した。進行膵癌に対するS-1療法は投与サイクルの短縮により,有効性を維持した消化器毒性の軽減が可能と考えられた。
目次
Summary
S-1 administration for 28 consecutive days followed by 14 days of rest(6-week cycle)is often chosen as second-line chemotherapy for advanced pancreatic cancer(PC), but it causes gastrointestinal toxicity. In comparison, in gastric cancer or head and neck cancer, S-1 administration for 14 consecutive days followed by a 7-day rest period(3-week cycle)reduced gastrointestinal toxicity. This study retrospectively evaluated the efficacy and safety of a 3-week S-1 schedule compared to a 6-week schedule in patients with gemcitabine(GEM)-refractory advanced PC. Fifty-seven patients were treated with the 6-week S-1 schedule and 68 patients were treated with the 3-week S-1 schedule. There were no statistical differences in overall survival(p=0.13)and progression-free survival(p=0.190). With regard to adverse events, the rates of nausea(p<0.01)and vomiting(p=0.04)were lower with the 3-week schedule than with the 6-week schedule. Thus, S-1 therapy with a 3-week schedule as second-line chemotherapy in patients with GEM-refractory advanced PC was associated with reduced gastrointestinal toxicity and similar efficacy, when compared to a 6-week schedule.
要旨
S-1の推奨用法は4週投与2週休薬(6週サイクル)であるが,胃癌や頭頸部癌において投与スケジュールを2週投与1週休薬(3週サイクル)に短縮することで,消化器毒性が軽減することが報告されている。本研究では,ゲムシタビン耐性進行膵癌に対してS-1療法を受けた患者125名(6週サイクル57名,3週サイクル68名)を対象として,投与スケジュール別の治療成績を比較検討した。両群間の全生存期間に差を認めないが,悪心や嘔吐の発現割合が3週サイクルで低下した。進行膵癌に対するS-1療法は投与サイクルの短縮により,有効性を維持した消化器毒性の軽減が可能と考えられた。